EGFR and colorectal carcinoma: For initial marker selection, we studied theexpression levels of three prominent biomarkers: VEGF, EGFR, and CEA;VEGF and EGFR are being utilized for the treatment of CRC in patientsusing the antibodies bevacizumab (targeting VEGF-A),42 aflibercept (targeting VEGF-A and VEGF-B),43 panitumumab, and cetuximab (targeting EGFR).44 CEA is a commonly used serum biomarker withhigh specificity for diagnosing CRC.